Benzinga Pro's 5 Stocks To Watch Today
Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user!
Biolinerx Ltd/S ADR (NASDAQ: BLRX) stock was trading higher by around 10 percent early Wednesday morning after the company was granted a patent approval. The clinical-stage biopharmaceutical company focused on oncology and immunology said it was granted a patent from the European Patent Office for its BL-8040 with cytarabine for the treatment of acute myeloid leukemia.
Marathon Patent Group Inc (NASDAQ: MARA) was trading lower by nearly 1.5 percent. A 13F filing from Dan Loeb's Third Point on Tuesday disclosed a new 2-million share stake in the IP licensing and commercialization company.
Macy's Inc (NYSE: M) was trading higher by more than 9 percent in reaction to the retailer's top-and-bottom line Q1 beat and lifted guidance. The company said it earned 48 cents per share in the first quarter on revenue of $5.54 billion versus expectations of 35 cents per share and $5.39 billion. Management lifted its fiscal 2018 EPS guidance from $3.55-$3.75 to a new range of $3.75-$3.95.
Euro Tech Holdings Company Ltd (NASDAQ: CLWT) was trading lower by more than 2 percent after a volatile trading session on Tuesday. Shares spiked after Tuesday's open above $6 only to trade below $3.50 in the afternoon. The distributor of advanced water treatment equipment is a low-float stock with around 2.2 million shares outstanding.
Evolus Inc (NASDAQ: EOLS) stock was trading lower by 8 percent before being halted. The lifestyle aesthetics company said the FDA issued a Complete Response Letter which cited deficiencies which were related to Chemistry, Manufacturing, and Controls processes which is not related to clinical or non-clinical matters.
Related Links:
A Peek Into The Markets: US Stock Futures Edge Higher Ahead Of Housing Starts, Industrial Production Data
26 Stocks Moving In Wednesday's Pre-Market Session
See more from Benzinga
© 2018 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
